<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Effective therapies for KRAS mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are a critical unmet clinical need </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we described GEMMs for <z:hpo ids='HP_0003745'>sporadic</z:hpo> Kras mutant and non-mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> suitable for preclinical evaluation of experimental therapeutics </plain></SENT>
<SENT sid="2" pm="."><plain>To accelerate drug discovery and validation, we sought to derive low-passage cell lines from GEMM Kras mutant and <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> for in vitro screening and transplantation into the native colonic environment of immunocompetent mice for in vivo validation </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: Cell lines were derived from Kras mutant and non-mutant GEMM <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> under defined media conditions </plain></SENT>
<SENT sid="4" pm="."><plain>Growth kinetics, phosphoproteomes, transcriptomes, drug sensitivity, and metabolism were examined </plain></SENT>
<SENT sid="5" pm="."><plain>Cell lines were implanted in mice and monitored for in vivo <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> analysis </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Kras mutant cell lines displayed increased proliferation, MAPK signaling, and PI3K signaling </plain></SENT>
<SENT sid="7" pm="."><plain>Microarray analysis identified significant overlap with human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-related gene signatures, including KRAS mutant and metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Further analyses revealed enrichment for numerous disease-relevant biological pathways, including <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="9" pm="."><plain>Functional assessment in vitro and in vivo validated this finding and highlighted the dependence of Kras mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> on oncogenic signaling and on aerobic glycolysis </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: We have successfully characterized a novel GEMM-derived orthotopic transplant model of human KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>This approach combines in vitro screening capability using low-passage cell lines that recapitulate human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and potential for rapid in vivo validation using cell line-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that develop in the colonic microenvironment of immunocompetent animals </plain></SENT>
<SENT sid="12" pm="."><plain>Taken together, this platform is a clear advancement in preclinical <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> models for comprehensive drug discovery and validation efforts </plain></SENT>
</text></document>